STAT2d
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...
New York Post15d
Eli Lilly plans to invest $27B to build four new US plants as tariffs loom
Eli Lilly has unveiled plans to invest $27 billion in the construction of four new manufacturing plants in the United States. Getty Images The new sites will be announced later this year and are ...
Is Eli Lilly Stock a Buy?
Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on ...
Fierce Pharma8d
Lilly's first DTC Ebglyss campaign highlights eczema’s effects on a range of skin tones and age groups
After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...
Eli Lilly CEO on $27 billion investment in U.S. manufacturing expansion
CNBC’s Angelica Peebles and Eli Lilly CEO David Ricks, join 'Squawk on the Street' to discuss the company's U.S.
Medical Marketing & Media9d
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.